Antisense oligonucleotides targeted to sequences in thymidylate synthase
(TS) mRNA. In particular the invention relates to antisense
oligonucleotides targeted to sequences in the 3' end of TS mRNA, which
are both cytostatic on their own when administered to human tumour cell
lines, and which also enhance the toxicity of anticancer drugs. The
invention further relates to a combination product comprising an
antisense oligonucleotide in combination with an anticancer agent such as
Tomudex or pemetrexed and to the use of such a combination product in the
treatment of cancer.